Skip to main content

Matthew B. Laurens, MD, MPH

Academic Title:

Associate Professor

Primary Appointment:

Pediatrics

Secondary Appointment(s):

Medicine

Location:

HSF-I, 480

Phone (Primary):

410-706-5328

Phone (Secondary):

410-706-8695

Fax:

410-706-1204

Education and Training

Oglethorpe University, B.S., Biology, 1992

The Johns Hopkins University Bloomberg School of Public Health, M.P.H., 1996

Mercer University School of Medicine, M.D., 2001

Internship and Residency, Tulane University School of Medicine, Pediatrics, 2001-2004

Chief Residency, Tulane University School of Medicine, Pediatrics, 2004-2005

Fellowship, University of Maryland School of Medicine, Pediatric Infectious Diseases and Tropical Pediatrics, 2005-2008

Biosketch

Dr. Laurens is a pediatric infectious disease specialist with a primary research interest in malaria and antimalarial immunity. He conducts studies at the Center for Vaccine Development (CVD) in Baltimore and at international sites in Burkina Faso, Mali, and Malawi. Dr. Laurens evaluates vaccines and therapeutics that target infectious pathogens, studies the interaction of HIV and malaria and investigates the acquisition of antimalarial immunity. The broad goal of Dr. Laurens’ research is to illuminate the mechanisms of immunity to malaria with the aim to inform development of malaria vaccines and therapeutics.

Research/Clinical Keywords

Malaria, typhoid, vaccines, antimalarial immunity, HIV-malaria, Burkina Faso, Mali, Malawi.

Highlighted Publications

Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono A, Nebié I, Konaté A, Berges GD, Diarra A, Ouedraogo M, Soulama I, Hema A, Datta S, Liang Y, Rotrosen E, Tracy JK, Jamka L, Oshinsky JJ, Pasetti MF, Neuzil KM, Laurens MB. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomised controlled phase 2 trial. Int J Infect Dis. 2021 May 31:S1201-9712(21)00461-6.

Laurens MB, Mungwira RG, Nampota N, Nyirenda OM, Divala TH, Kanjala M, Mkandawire FA, Galileya LT, Nyangulu W, Mwinjiwa E, Downs M, Tillman A, Taylor TE, Mallewa J, Plowe CV, van Oosterhout JJ, Laufer MK. Revisiting Co-Trimoxazole Prophylaxis for African Adults in The Era of Antiretroviral Therapy: A Randomized Controlled Clinical TrialClin Infect Dis2021 Mar 21[Epub ahead of print] 

Friedman-Klabanoff DJ, Berry AA, Travassos MA, Cox C, Zhou Y, Kotloff KL, Nomicos EYH, Deye GE, Pasetti MF, Laurens MBLow dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is highly immunogenic in Phase 1 first-in-human clinical testing. Vaccine. 2021 Feb 22;39(8):1195-1200.

Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono AB, Nébié I, Konaté AT, Berges GD, Diarra A, Ouedraogo M, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, Neuzil KM, Laurens MBSafety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina FasoInt J Infect Dis2021 Jan;102:517-523.
 
Laps AM, Foster CB, Laurens MB. High-dose dexamethasone in a child with enteric encephalopathy caused by Salmonella enterica serovar Typhi. The Pediatric Infectious Disease Journal. Pediatr Infect Dis J. 2020 May;39(5):e49-e51.

Laurens MB. RTS,S/AS01 Vaccine (Mosquirix™) : An overview. Hum Vaccin Immunother. 2020 Mar 3;16(3):480-489.

Laurens MB, Berry AA, Travassos MA, Strauss K, Adams M, Shrestha B, Li T, Eappen A, Manoj A, Abebe Y, Murshedkar T, Gunasekera A, Richie TL, Lyke KE, Plowe CV, Kennedy JK, Potter GE, Deye GA, Sim BKL, Hoffman SL. Dose dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naïve adults. J Infect Dis. 2019 Nov 6;220(12):1962-1966. 

Laurens MB*, Meiring JE*, Patel P, Patel P, Misiri T, Simiyu K, Mwakiseghile F, Tracy K, Masesa C, Liang Y, Henrion M, Rotrosen E, Gmeiner M, Heyderman R, Kotloff KL, Gordon MA, Neuzil KM. TyVAC Malawi: a phase III randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children age 9 months through 12 years in Blantyre, Malawi: study protocol for a randomized controlled trial. Clin Infect Dis. 2019 Mar 7;68(Supplement_2):S50-S58. *co-first authors. PMC6405268.

Laurens MB, Sirima SB, Rotrosen E, Siribie M, Tiono A, Ouedraogo A, Liang Y, Kotloff KL, Neuzil KM. A phase 2 randomized, double-blind controlled safety and immunogenicity trial of typhoid conjugate vaccine in children under two years of age in Ouagadougou, Burkina Faso. Clin Infect Dis. 2019 Mar 7;68(Supplement_2):S59-S66. PMC6405275.

Laurens MBThe promise of a malaria vaccine—are we closer? Annual Review of Microbiology. 2018 Sep 8;72:273-292.

View a complete list of Dr. Laurens' publications

Research Interests

Dr. Laurens is interested in vaccine development and clinical testing, including vaccines for cholera, malaria, and typhoid fever; immune responses to vaccination; antimalarial immunity; and HIV-malaria coinfection.

Clinical Specialty Details

Pediatric Infectious Diseases

Awards and Affiliations

American Academy of Pediatrics

American Academy of Pediatrics

American Society of Tropical Medicine and Hygiene

Infectious Diseases Society of America

HIC-Vac Network (Human Infection Challenge)

Pediatric Infectious Diseases Society

Grants and Contracts

Matthew Laurens, M.D. (co-PI)

NIH HHSN272201300022I contract, PI: Kotloff, Vaccine and Treatment Evaluation Units

6/15/20-12/31/22

National Institutes of Health (NIH)

A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older

  • Co-leading effort to recruit and vaccinate 500 participants at our site for the first COVID-19 Phase 3 vaccine trial in the U.S.

 

Miriam Laufer, M.D. (PI)
Matthew Laurens, M.D. (Lead co-investigator, DAIDS CRS lead)
U01AI089342
8/1/11-7/31/21 
National Institutes of Health (NIH)
Clinical Trial of Trimethoprim-sulfamethoxazole or Chloroquine in Adults on ART

  • Clinical trial that will guide Malawi health policy and ultimately affect the health of millions of ART recipients by providing evidence to determine whether to stop TS prophylaxis in person on ART and the importance of preventing HIV-associated opportunistic infections and malaria in persons who are stable on ART.

 

Matthew Laurens, M.D. (Protocol PI)

NIH HHSN272201300022I contract, PI: Kotloff, Vaccine and Treatment Evaluation Units

8/6/14-12/31/22

National Institutes of Health (NIH)

A Phase 1 Challenge Study to Evaluate Safety, Immunogenicity and Efficacy of a Malaria Vaccine (rCSP adjuvanted with GLA-LSQ), in Healthy Adults, DMID 13-0088

  • Successfully responded to NIH request for task, drafted study protocol, leading study activities.

 

Matthew Laurens, M.D. (Protocol PI)

NIH U01AI112367

1/1/15-12/31/21 

National Institutes of Health (NIH)

Safety and Efficacy of PfSPZ Vaccine in Malaria-Exposed Adults [in Burkina Faso]

  • Develop research objectives, study protocol, train and supervise study staff, oversee data analysis, presentations to safety committees and research community

 

Kathleen Neuzil, M.D. (PI)

Matthew Laurens, M.D. (co-Investigator and site PI)

10/24/16-10/30/21 

The Bill and Melinda Gates Foundation, 10018733

Accelerating Availability and Access to Typhoid Conjugate Vaccines

  • Coordinate and harmonize study protocols for three clinical trials to test a typhoid conjugate vaccine
  • Lead study activities at Ndirande Research Clinic, Blantyre Malaria Project, Blantyre, Malawi

 

Matthew Laurens, M.D. (PI)

11/30/18-1/31/22  

SEEK UK

Universal Mosquito Vaccine

  • First-in-human clinical trial to test a universal mosquito saliva vaccine

In the News

Selected media:

How can a tapeworm cause cancer? CNN online. November 9, 2015.

Parasite antigen shows promise as a malaria vaccine. Reuters online. April 27. 2020.

How close is a coronavirus vaccine? PolitiFact online.  May 12, 2020

Typhoid conjugate vaccine safe, effective when administered with meningococcal A. Healio online. June 18, 2020

Here’s how we’ll know when a COVID-19 vaccine is ready. National Geographic online. June 30, 2020.

A coronavirus vaccine: Where does it stand? PolitiFact online. July 13, 2020.

Fact-checking Joe Biden on a coronavirus vaccine. PolitiFact online. September 17, 2020.

Interviewed by Maryland Public Television’s Jeff Salkin, Direct Connection, Your Health Segment, “Your Health: An Update on COVID-19 Vaccines and Clinical Trials”, September 22, 2020.

What does Pfizer’s COVID-19 announcement mean for you. PolitiFact online. November 12, 2020.

COVID-19 vaccine update: What to know about Pfizer and Moderna’s announcements. PolitiFact online November 16, 2020.

HEALTH CARE BRIEFING: Biden Picks California AG Becerra for HHS. Bloomberg Government online. December 7, 2020.

Many Americans say they don’t want a vaccine. Should we be worried? PolitiFact online. December 8, 2020.

What to expect when you’re injected: Vaccine side effects explained. STAT news online. December 22, 2020.

The data gaps in the fight against COVID-19: Experts point out what we still don’t know. PolitiFact online. February 3, 2021.

You’re fully vaccinated against COVID-19. What can you do now?. Poynter online. March 11, 2021.

Experts reject claim that supplements can counter COVID-19 vaccines. Agence France-Presse online. April 29, 2021.

As the COVID-19 pandemic evolves, we answer 7 lingering vaccine questions. ScienceNews.org. May 11, 2021.

Fact check: Post misleads on effectiveness of J&J COVID-19 vaccine in older adults. USA Today. June 6, 2021.

 

Community Service

Pediatrician Consultant for local child care centers: Downtown Baltimore Child Care Center, Homewood Early Learning Center, and Harry & Jeanette Weinberg Early Childhood Center

Participant, Senator Benjamin Cardin’s roundtable discussion on Zika virus preparedness and funding

Professional Activity

Judge, Young Investigator Award Competition, Annual Meeting of the American Society of Tropical Medicine and Hygiene

Member, Global Burden of Disease collaborator network, Institute for Health Metrics and Evaluation

Member, Program and Meetings Committee, Pediatric Infectious Diseases Society (PIDS)

Member, Malaria/Tropical Diseases External Working Group, Infectious Diseases Clinical Research Consortium (IDCRC) for the Vaccine Treatment and Evaluation Unit (VTEU) network, NIH/DMID

Member, Training and Education Committee, Infectious Diseases Clinical Research Consortium (IDCRC) for the Vaccine Treatment and Evaluation Unit (VTEU) network, NIH/DMID

Lab Techniques and Equipment

Dr. Laurens uses malaria microscopy for malaria diagnosis and speciation, and genomic sequencing for analysis of antimalarial resistance and malaria vaccine resistance.

Links of Interest